Basic Info

300 Corporate Court Suite 8
South Plainfield, NJ 07080
(908) 444-4660
Preferred contact:
  Glenn Kazo - President/CEO
Prolong Pharmaceuticals Inc
Business Identifier: NO Business Identifier is currently available for this company.
Public Profile:
Prolong Pharmaceuticals creates proprietary, high-value biopharmaceuticals utilizing a delivery system known as PEGylation. PEGylation is the only FDA-approved protein delivery technology that transforms proteins into superior drug products, by attaching a polyethylene glycol ("PEG") polymer to a therapeutic protein. This process, developed by the company's founder, results in an improved product with significantly enhance potency, fewer side effects, and a reduced dosing frequency

 Synopsis: Awardee Business Condition
Year Founded 2002 IP Holdings N/A
Employee Range 1-4 VC funded? Yes
Revenue Range Less than .5M Private/Public Privately Held
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
2009 2 NIH $848,378 Development Of Peg Hemoglobin Blood Substitute To Treat Hemorrhagic Shock
2009 2 NIH $848,378 Development of PEG Hemoglobin blood substitute to treat hemorrhagic shock


Media coverage